Effect of probiotic and selenium co-supplementation in the treatment of schizophrenia patients

The effects of combined probiotic and selenium supplementation on clinical status and metabolic profiles in patients with schizophrenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N41

Enrollment

Registered

2018-11-18

Start date

2018-09-17

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Probiotic oral capsule containing four strains of Lactobacillus acidophilus (2×109 CFU/g), Bifidobacterium lactis (2×109 CFU/g), Bifidobacterium bifidum (2×109 CFU/

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with schizophrenia Individuals aged 18 to 60 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria: patients with metabolic syndrome diabetes mellitus liver and kidney insufficiency thyroid disorders

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome Scale (PANSS). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical Examination.	—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Brief Psychiatric Rating Scale. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical examination.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Brief Psychiatric Rating Scale. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Jamilian

Arak University of Medical Sciences

jamilian_h@aums.ac.ir+98 86 3277 4031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026